WHO Sounds Alert Over Acute Scarcity of Weight-Loss Injections
Fewer than 10% of people who could benefit from weight-loss injections such as Wegovy have access to them, states the WHO as it issues its initial recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is urging more widespread and fairer availability to these injectable treatments.
Per projections, over two billion will be living with obesity by 2030 if no action is taken.
"The new guidance acknowledges that excess weight is a long-term condition that can be treated with holistic and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are significant hurdles to universal access to the treatments that can assist patients in reducing substantial weight, explains the body.
Skinny Jab Scarcity
Even under the current best projected case, the production of such drugs might only reach around 100 million people โ fewer than 10% of eligible patients, per the health organization.
The guideline urges nations and manufacturers to expand access, by measures including patent sharing.
The intellectual property rights on the active ingredient โ the core ingredient of a leading brand โ is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Drugs Function
The injections mimick a natural hormone to slow digestion, reduce hunger and enhance feelings of fullness so people consume fewer calories.
Patients usually see weight reduction in the initial weeks of commencing the weekly injections.
Evidence suggests people may regain a significant portion after a year of discontinuing the treatment, as their normal appetite resume.
Being above a healthy weight increases your likelihood for contracting diseases, like type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight affects individuals in all nations and was responsible for millions of deaths worldwide in 2024, according to the WHO.
